Lactobacillus rhamnosus R0011 and Improved Sinonasal Quality of Life

Doses used in studies

cells/day: 500 million (median 500 million, IQR 500 million–500 million) — 1 study

Time to effect

Median: 4 weeks · IQR 4 weeks–4 weeks · Range 4 weeks–4 weeks — Reported in 1 of 1 study

Safety in these studies

Overall tolerabilityNo significant difference
No difference in medication use or side effects between the two study groups.
from: Probiotics as adjunctive treatment for chronic rhinosinusitis: a randomized controlled tri

1 of 1 paper

Probiotics as adjunctive treatment for chronic rhinosinusitis: a randomized controlled trial.

2009-02
RCT · n = 77
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 140(2)
- Shraddha S Mukerji
- Melissa A Pynnonen
- Hyungjin Myra Kim
- Andrew Singer
- Mark Tabor
- Jeffrey E Terrell

PubMed: 19201289
DOI: 10.1016/j.otohns.2008.11.020

3 Insights on

Improved Sinonasal Quality of Life

High evidence
Clinical

No significant differences were found between the probiotic and placebo groups in mean changes from baseline to 4 weeks (P = 0.79) or from baseline to 8 weeks (P = 0.23).

Effect: Neutral
Effect size: Small
Significant: No
Dose: 500 million active cells/tablet twice daily